Human chorionic gonadotropin (hCG) is a hormone made by the placenta and a prescription drug in the United States. This guide covers its structure, action, labeled uses, key studies, side effects and regulatory status. Every source was checked on November 17, 2026.
Quick answer: hCG is a prescription-only hormone drug. Its labels cover certain cases of undescended testes in boys, pituitary-related hypogonadism in men, and ovulation-related infertility in women. FDA says hCG is not approved for weight loss. It is also a standard reference material for laboratory hCG assays.
Vitrapep does not sell hCG; this page is a reference summary of published research and regulatory information. It is not medical advice.
What is hCG?
hCG is a hormone the placenta makes during pregnancy. The current urinary hCG label calls it “a polypeptide hormone produced by the human placenta” made of an alpha and a beta subunit (chorionic gonadotropin label, 2025). Its alpha subunit is essentially the same as in LH, FSH and TSH. The beta subunits differ.
There are two kinds of approved hCG. Urinary hCG is purified from the urine of pregnant women, the label says. Recombinant hCG, called choriogonadotropin alfa, is made in genetically modified Chinese hamster ovary cells. Its label describes “a water soluble glycoprotein consisting of two non-covalently linked subunits” of 92 and 145 amino acids (Ovidrel label, 2023). That makes hCG a protein, not a short peptide (see peptides versus proteins).
hCG: key facts
| Fact | Detail |
|---|---|
| Structure | Glycoprotein of two non-covalently linked subunits: alpha (92 amino acids) and beta (145 amino acids) |
| Class | Gonadotropin; LH-like hormone; licensed biological product |
| Molecular formula | Not given; a glycosylated protein has no single small-molecule formula |
| Molecular weight | Not stated in the labels we read |
| First FDA approval | Oldest listed: March 5, 1973 (urinary hCG); recombinant Ovidrel: September 20, 2000 |
| Brand names | Novarel, Pregnyl (urinary); Ovidrel (recombinant); unbranded chorionic gonadotropin |
The dates come from FDA’s 2020 list of drug applications that became biologics licenses (FDA, 2020). It also dates Novarel to 1974 and Pregnyl to 1976.
How does hCG work?
hCG copies the signal of LH, a pituitary hormone. The urinary hCG label states that “the action of HCG is virtually identical to that of pituitary LH.” It also has a small amount of FSH-like activity.
In men, hCG stimulates Leydig cells in the testes to make androgens such as testosterone. In women, it stimulates the corpus luteum in the ovary to make progesterone. The recombinant label says choriogonadotropin alfa binds the LH/hCG receptor on ovarian granulosa and theca cells.
The urinary hCG label also states what hCG does not do. It has no known effect on fat mobilization, appetite, sense of hunger or body fat distribution. These label statements rest on human pharmacology.
What is hCG approved for?
The urinary hCG label, revised in February 2025, lists three indications:
- “Prepubertal cryptorchidism not due to anatomical obstruction.” Cryptorchidism means undescended testes.
- “Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males.”
- Induction of ovulation and pregnancy in certain anovulatory, infertile women, as the label defines them.
The Ovidrel label covers two uses in infertile women. One is final follicular maturation within assisted reproductive technology programs. The other is ovulation induction when infertility is functional, not primary ovarian failure.
The urinary label opens with a warning in capital letters. It states that hCG “has not been demonstrated to be effective adjunctive therapy in the treatment of obesity.” It adds that there is no substantial evidence that hCG increases weight loss beyond calorie restriction.
What did the key trials show?
Obesity meta-analysis (1995, human trials). Lijesen and colleagues reviewed 8 controlled and 16 uncontrolled trials of hCG with the Simeons diet (Lijesen et al., 1995). Quality scores ranged from 16 to 73 out of 100. Of the 12 studies scoring 50 or more, only one called hCG a useful adjunct. The authors concluded that “there is no scientific evidence that HCG is effective in the treatment of obesity.”
Recombinant versus urinary hCG (2001, human). A phase 3, double-blind, randomized trial ran at 19 infertility centers (International Recombinant hCG Study Group, 2001). It enrolled 198 women with WHO group II anovulation. The main outcome was ovulation, confirmed by a progesterone test. Ovulation rates were 95.3% with recombinant hCG and 88.0% with urinary hCG, meeting the equivalence margin. Fewer women reported local reactions with recombinant hCG. We found no NCT number for this trial.
What side effects does the label list?
Neither label we read carries a boxed warning. The urinary hCG label lists these adverse reactions: headache, irritability, restlessness, depression, fatigue, edema, precocious puberty and gynecomastia. It also lists local pain where the drug was given.
Its warnings include ovarian hyperstimulation syndrome, rupture of ovarian cysts, multiple births and arterial thromboembolism. It notes that “anaphylaxis and other hypersensitivity reactions have been reported with urinary-derived HCG products.” Contraindications include precocious puberty, prostate cancer or other androgen-dependent tumors, and prior allergic reaction to hCG.
In the Ovidrel label, the most frequent events were application site disorders. They affected 14.0% of patients in the assisted reproduction table and 16.2% in the ovulation induction table. Its warnings also cover pulmonary and vascular complications.
What is hCG’s regulatory status, and is it used in research?
Prescription only. FDA states that hCG “is not approved for use without a prescription for any purpose” and that “it is not approved for weight loss” (FDA consumer update). The same page says FDA has approved hCG as a prescription drug for female infertility and other conditions.
A biologic since 2020. On March 23, 2020, approved hCG drug applications were deemed biologics licenses. FDA’s notice to compounders named human chorionic gonadotropin among substances affected by this change (FDA, 2020). From that date, transitioned biological products no longer qualify for the compounding exemptions in sections 503A and 503B. Our article on 503A compounding categories covers the wider framework.
Sport. WADA’s 2026 Prohibited List names “chorionic gonadotrophin (CG)” under S2.2.1, “Testosterone-stimulating peptides in males.” S2 substances are prohibited at all times, in and out of competition. Athletes should check with their anti-doping organization. See our guide to peptides on the 2026 WADA list.
Laboratory use. The WHO 6th International Standard for hCG, coded 18/244, was established in October 2020 (NIBSC). It is intended for calibrating hCG bioassays and immunoassays. Its leaflet states that it “is not for administration to humans or animals in the human food chain.” See research use only explained.
hCG acts on the gonads. Kisspeptin, GnRH and GnRH analogs act higher up; see our gonadorelin and leuprolide guides and peptide hormones.
Frequently asked questions about hCG
Is hCG FDA-approved for weight loss?
No. FDA states it is not approved for weight loss. The label states that hCG has not been shown to be effective for obesity.
Can hCG be sold without a prescription?
No. FDA states that hCG is not approved for use without a prescription for any purpose.
Is hCG a peptide or a protein?
It is a glycoprotein. Its two subunits have 92 and 145 amino acids, which places it among proteins rather than short peptides.
Is hCG banned in sport?
Yes, for males. WADA’s 2026 list names chorionic gonadotrophin under S2.2.1, testosterone-stimulating peptides in males, prohibited at all times.
What to know now
- Approval: prescription only; oldest listed FDA approval March 5, 1973; a licensed biologic since March 23, 2020.
- Labeled uses: certain cases of cryptorchidism, male hypogonadotropic hypogonadism and female infertility.
- Weight loss: not approved; the label and a 1995 meta-analysis found no evidence it works.
- Sport: prohibited in males at all times under WADA S2.2.1.
- Laboratory: a WHO International Standard exists for calibrating hCG assays.
What we’re watching
Label revisions for urinary and recombinant hCG on DailyMed. Any FDA action on hCG compounding or biosimilar hCG products. And WADA’s 2027 Prohibited List, which takes effect on January 1, 2027.